CULLINAN THERAPEUTICS, INC. (CGEM) Shareholder Equity
- 2026-06-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $6.00K; Additional Paid in Capital, Common StockUSD $1.01B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-134.00K.
- 2026-03-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $6.00K; Additional Paid in Capital, Common StockUSD $1.00B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $127.00K.
- 2025-12-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $6.00K; Additional Paid in Capital, Common StockUSD $995.82M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $1.02M.
- 2025-09-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $6.00K; Additional Paid in Capital, Common StockUSD $987.80M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $973.00K.
CULLINAN THERAPEUTICS, INC. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Preferred Stock, Value, Issued USD | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest USD | Noncontrolling Interest, Increase from Subsidiary Equity Issuance USD | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD | Noncontrolling Interest, Increase from Business Combination USD |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 | $6.00K | $1.01B | $-134.00K | $-691.48M | (m) | $321.75M | (m) | (m) | (m) |
| 2026-03-31 | $0.00 | $6.00K | $1.00B | $127.00K | $-637.78M | (m) | $366.17M | (m) | (m) | (m) |
| 2025-12-31 | $0.00 | $6.00K | $995.82M | $1.02M | $-588.12M | $408.73M | $408.73M | (m) | (m) | (m) |
| 2025-09-30 | $0.00 | $6.00K | $987.80M | $973.00K | $-537.41M | $451.37M | $451.37M | (m) | (m) | (m) |
| 2025-06-30 | $0.00 | $6.00K | $978.33M | $607.00K | $-486.80M | $492.15M | $492.15M | (m) | (m) | (m) |
| 2025-03-31 | $0.00 | $6.00K | $968.07M | $505.00K | $-416.74M | $551.84M | $551.84M | (m) | (m) | (m) |
| 2024-12-31 | $0.00 | $6.00K | $958.70M | $-133.00K | $-368.24M | $590.33M | $590.33M | (m) | (m) | (m) |
| 2024-09-30 | $0.00 | $6.00K | $947.48M | $970.00K | $-320.59M | $627.86M | $627.86M | (m) | (m) | (m) |
| 2024-06-30 | $0.00 | $6.00K | $936.72M | $-476.00K | $-280.03M | $656.22M | $656.22M | (m) | (m) | (m) |
| 2024-03-31 | $0.00 | $4.00K | $664.00M | $-331.00K | $-238.00M | $425.67M | $425.67M | (m) | (m) | (m) |
| 2023-12-31 | $0.00 | $4.00K | $654.68M | $-129.00K | $-200.86M | $453.70M | $453.89M | 12 month · $2.13M | (m) | (m) |
| 2023-09-30 | $0.00 | $4.00K | $646.92M | $-1.05M | $-177.05M | $468.82M | $468.82M | (m) | (m) | (m) |
| 2023-06-30 | $0.00 | $4.00K | $639.07M | $-1.62M | $-137.87M | $499.57M | $499.57M | (m) | (m) | (m) |
| 2023-03-31 | $0.00 | $4.00K | $592.54M | $-1.24M | $-105.66M | $485.65M | $485.65M | 3 month · $179.00K | (m) | (m) |
| 2022-12-31 | $0.00 | $5.00K | $585.32M | $-2.60M | $-47.70M | $535.03M | $535.03M | 12 month · $1.53M | 12 month · $22.87M | (m) |
| 2022-09-30 | (m) | $5.00K | $610.97M | $-3.93M | $-20.91M | $586.13M | $586.13M | (m) | (m) | (m) |
| 2022-06-30 | (m) | $5.00K | $604.27M | $-3.63M | $3.89M | $604.54M | $604.62M | 3 month · $139.00K | (m) | (m) |
| 2022-03-31 | (m) | $4.00K | $592.84M | $-3.13M | $-171.01M | $418.70M | $419.47M | 3 month · $1.15M | (m) | (m) |
| 2021-12-31 | (m) | $4.00K | $584.71M | $-838.00K | $-158.91M | $424.97M | $425.37M | 12 month · $990.00K | 12 month · $22.87M | (m) |
| 2021-09-30 | (m) | $4.00K | $569.84M | $-58.00K | $-126.39M | $443.39M | $445.47M | (m) | (m) | (m) |
| 2021-06-30 | (m) | $4.00K | $564.71M | $-115.00K | $-109.05M | $455.55M | $458.54M | (m) | (m) | (m) |
| 2021-03-31 | (m) | $4.00K | $560.37M | $-60.00K | $-93.41M | $466.90M | $469.70M | (m) | 3 month · $22.87M | (m) |
| 2020-12-31 | (m) | $3.00K | $292.35M | $-2.00K | $-93.34M | $199.01M | $200.31M | (m) | (m) | 12 month · $5.67M |
| 2020-09-30 | (m) | $2.00K | $152.58M | $59.00K | $-64.99M | $87.65M | $89.51M | (m) | (m) | (m) |
| 2020-06-30 | (m) | $2.00K | $152.58M | $203.00K | $-55.13M | $97.65M | $98.92M | (m) | (m) | 3 month · $5.67M |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | $106.77M | (m) | (m) | (m) |
| 2019-12-31 | (m) | $2.00K | $138.54M | $-4.00K | $-41.54M | $97.00M | $97.86M | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |